It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Rapid, inexpensive, robust diagnostics are essential to control the spread of infectious diseases. Current state of the art diagnostics are highly sensitive and specific, but slow, and require expensive equipment. Here we report the development of a molecular diagnostic test for SARS-CoV-2 based on an enhanced recombinase polymerase amplification (eRPA) reaction. eRPA has a detection limit on patient samples down to 5 viral copies, requires minimal instrumentation, and is highly scalable and inexpensive. eRPA does not cross-react with other common coronaviruses, does not require RNA purification, and takes ~45 min from sample collection to results. eRPA represents a first step toward at-home SARS-CoV-2 detection and can be adapted to future viruses within days of genomic sequence availability.
Current state-of-the-art diagnostics for infectious diseases are sensitive but require extensive equipment. Here the authors develop an enhanced recombinase polymerase amplification reaction for SARS-CoV-2 that allows for inexpensive and rapid testing with minimal equipment.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details







1 Harvard Medical School, Department of Systems Biology, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Harvard Medical School, Laboratory of Systems Pharmacology, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Harvard Medical School, Biological and Biomedical Sciences Program, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X)
2 Harvard Medical School, Department of Systems Biology, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Harvard Medical School, Laboratory of Systems Pharmacology, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X)
3 Harvard Medical School, Laboratory of Systems Pharmacology, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X)
4 Harvard Medical School, Department of Systems Biology, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X)
5 Harvard Medical School, Brigham and Women’s Hospital, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X)
6 Harvard Medical School, Brigham and Women’s Hospital, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Massachusetts Consortium on Pathogen Readiness, Boston, USA (GRID:grid.38142.3c)
7 Harvard Medical School, Department of Systems Biology, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Harvard Medical School, Laboratory of Systems Pharmacology, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Massachusetts Consortium on Pathogen Readiness, Boston, USA (GRID:grid.38142.3c)